Michael Reilly

Michael Reilly has 30 years of international leadership experience in marketing, business development, finance, and strategy at Amgen, Baxter, Sanofi, and Sterling Drug.

He is a co-leader of 20 development teams in neuroscience and other therapeutic areas including the blockbuster denosumab valued over $11B and also a member of core team on acquisition of Immunex and Enbrel®, the largest in biotech history at $16B

Michael has a BA in Molecular Biology from the University of California, Berkeley & MBA from the University of Michigan, Ann Arbor.